Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast To 2030

Publishing Date : March, 2022
Report Code : HCPH 0099
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Over the past 50 years, the nuclear medicine field has displayed a strong link between investments in chemistry and the development of radionuclide and radio-labeled compounds which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular levels for probing, tracking tissue function, studying disease progression and assessing treatment responses.

The nuclear medicine global market is poised to grow at a mid single digit CAGR from 2021 to 2030 to reach $11,362.0 million by 2030. Increasing radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy-based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.

The nuclear medicinal market is classified based on modality into diagnosis and therapeutics. The diagnostics market commanded the largest market and is expected to grow at a mid single digit CAGR from 2021 to 2030 due to an increase in SPECT and PET procedures. The therapeutics segment is projected to grow at double digit CAGR from 2021 to 2030 due to technological advancements in the targeted treatment of cancers. Potential new radioisotopes in the pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnostics market based on products is segmented into SPECT and PET among which, SPECT market commanded the largest revenue in 2021 and is expected grow at low single digit CAGR from 2021 to 2030 due to an increase in TC-99m isotope applications and product approvals. The SPECT market is further segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xenon (Xe-133), Rhenium (Re-186) and others. Among them, Technetium (Tc-99m) accounted for the largest share in 2021 and is projected to grow at low single digit CAGR from 2021 to 2030 due to its extensive usage in various diagnostic applications and emerging sources to meet the demand. SPECT market based on application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. The cardiology segment accounted for the largest share in 2021 and is expected to grow at low single digit CAGR from 2021 to 2030 due to an increase in the number of cardiac imaging cases using Tc-99m. Oncology is expected to grow at mid single digit CAGR from 2021 to 2030 due to the increasing use of SPECT isotopes in early screening tests in vulnerable populations in various developed countries.

PET is projected to grow at mid single digit CAGR from 2021 to 2030 due to an increase in the adoption of cyclotron for the production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2021 and the market is expected to grow at mid single digit CAGR from 2021 to 2030. Gallium (Ga-68) is expected to grow at high teen CAGR from 2021 to 2030 due to an increase in usage as theranostic pair in assessing the suitability of the patient for Lutathera and many emerging targeted radiotherapy agents. PET isotopes based on applications are further segmented into oncology, neurology, cardiology, inflammation and others. The oncology segment accounted for the largest share in 2021 and is projected to grow at high single digit CAGR from 2021 to 2030 due to an increase in the patient pool of lung, thyroid, brain breast cancer and dementia-related conditions.

The therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. The beta radiation segment accounted for the largest share in 2021 and is projected to grow at mid double digit CAGR from 2021 to 2030. Beta radiation therapy based on isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. The Lu-177 segment commanded the largest share in 2021 and is expected to grow at double digit CAGR from 2021 to 2030 due to the increased adoption of Lu-177 based radiopharmaceuticals for the treatment of neuroendocrine tumors and the anticipated launch of new treatment products based on the isotope. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others, among which, I-125 segment accounted for the largest share in 2021 and is projected to grow at mid single digit CAGR from 2021 to 2030 due to increasing usage in the treatment of lung cancer, prostate cancer, eye-related disease (retinoblastoma and eye plaque) and brain cancer. The therapeutic nuclear medicine market based on application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors (GEP-NETs), metastatic bone cancer, breast cancer and others, among which, The GEP-NETs market accounted for the largest share in 2021 and is expected to grow at mid teen CAGR from 2021 to 2030. Prostate Cancer is expected to grow at mid teen CAGR from 2021 to 2030 due to the advanced clinical trial stage (phase 3) and the predicted launch of the Lu-177 PSMA-617 product in the coming years.

The nuclear medicine market based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers, and others, among which, the hospitals segment accounted for the largest share in 2021 and is projected to grow at high single digit CAGR from 2021 to 2030 due to the ready availability of cyclotrons for the generation of isotope and use of advanced hybrid imaging.

Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer Group (Germany), GE Healthcare (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), and Fujifilm Holding Corporation (Japan).

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAY
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
        • 2.6.7.1     PROCEDURAL VOLUME ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING APPLICATIONS OF RADIOPHARMACEUTICALS
        • 3.3.1.2     PRODUCTION OF RADIOPHARMACEUTICALS FROM CYCLOTRONS
        • 3.3.1.3     EFFICIENT DIAGNOSIS AND TREATMENTS
        • 3.3.1.4     INCREASING INTEREST IN THERANOSTICS
        • 3.3.1.5     RISE IN PUBLIC AWARENESS
        • 3.3.1.6     TECHNOLOGICAL ADVANCEMENTS
        • 3.3.1.7     INCREASING DEMAND IN EMERGING MARKETS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     THE SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS
        • 3.3.2.2     HIGH COST AND SUPPLY SHORTAGE OF ISOTOPES
        • 3.3.2.3     RADIO TOXICITY
        • 3.3.2.4     SHORTAGE OF QUALIFIED TECHNICIANS
        • 3.3.2.5     WITHDRAWAL OF RADIOPHARMACY PRODUCTS DUE TO LIMITED COMMERCIAL ADOPTION
        • 3.3.2.6     REGULATORY ISSUES
        • 3.3.2.7     THREAT FROM TRADITIONAL/ALTERNATIVE DIAGNOSTIC PROCEDURES
        • 3.3.2.8     HUGE CAPITAL INVESTMENT
    • 3.4     PROBLEM AREAS
      • 3.4.1     CLOSURE OF REACTORS
    • 3.5     WINNING IMPERATIVES
      • 3.5.1     AVAILABILITY OF TECHNETIUM
    • 3.6     REGULATORY GUIDELINES
      • 3.6.1     UNITED STATES
      • 3.6.2     EUROPE
      • 3.6.3     JAPAN
      • 3.6.4     INDIA
      • 3.6.5     CHINA
      • 3.6.6     SOUTH KOREA
      • 3.6.7     SOUTH AFRICA
    • 3.7     REIMBURSEMENT SCENARIO AND CHALLENGES
    • 3.8     CLINICAL TRIALS
    • 3.9     TECHNOLOGICAL ADVANCEMENTS
      • 3.9.1     COMPTON CAMERA
      • 3.9.2     SUBTLE PET
      • 3.9.3     PRODUCTION OF ISOTOPES THROUGH CYCLOTRONS
      • 3.9.4     LINAC BASED TC-99M PRODUCTION
      • 3.9.5     AUGER ELECTRONS
    • 3.1     SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
      • 3.10.1     REACTORS/IRRADIATORS
      • 3.10.2     PROCESSING FACILITY
      • 3.10.3     GENERATORS
      • 3.10.4     HOSPITALS AND CENTRAL RADIO PHARMACIES
      • 3.10.5     CYCLOTRON
      • 3.10.6     LINAC BASED TC-99M PRODUCTION METHOD
    • 3.11     LIST OF FDA APPROVED RADIOPHARMACEUTICALS
    • 3.12     PORTER'S FIVE FORCE ANALYSIS
      • 3.12.1     THREAT OF NEW ENTRANTS
      • 3.12.2     THREAT OF SUBSTITUTES
      • 3.12.3     COMPETITIVE RIVALRY
      • 3.12.4     BARGAINING POWER OF SUPPLIERS
      • 3.12.5     BARGAINING POWER OF BUYERS
    • 3.13     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.13.1     NUCLEAR MEDICINE MARKET
      • 3.13.2     SPECT MARKET
      • 3.13.3     PET MARKET
      • 3.13.4     NUCLEAR MEDICINE THERAPEUTICS MARKET
      • 3.13.5     TC-99 MARKET
      • 3.13.6     F-18 MARKET
      • 3.13.7     GA-68 MARKET
      • 3.13.8     SR-82/RB-82 MARKET (IRRADIATORS, SEPERATION AND GENERATORS)
    • 3.14     NUCLEAR MEDICINE-FUNDING SCENARIO
    • 3.15     NUCLEAR MEDICINE – DEALS AND APPROVALS
    • 3.16     SPECT, PET AND CYCLOTRONS INSTALLED BASE
    • 3.17     CURRENT PRODUCTION CAPACITY AND DEMAND OF SELECT ISOTOPES
    • 3.18     EMERGING ISOTOPES
    • 3.19     LIST OF ISOTOPES PRODUCED USING 70 MEV CYCLOTRON AND COST ANALYSIS
  • 4     NUCLEAR MEDICINE GLOBAL MARKET, BASED ON MODALITY
    • 4.1     INTRODUCTION
    • 4.2     DIAGNOSTICS
      • 4.2.1     DIAGNOSTIC NUCLEAR MEDICINE BASED ON ISOTOPES
        • 4.2.1.1     SPECT, BASED ON ISOTOPES
          • 4.2.1.1.1     TECHNETIUM (TC-99M)
          • 4.2.1.1.2     THALLIUM (TL-201)
          • 4.2.1.1.3     GALLIUM (GA-67)
          • 4.2.1.1.4     IODINE (I-123)
            • 4.2.1.1.4.1     SUPPLY CHAIN ANALYSIS OF IODINE-123 (I-123)
          • 4.2.1.1.5     XENON (XE-133)
          • 4.2.1.1.6     RHENIUM (RE-186)
          • 4.2.1.1.7     OTHERS (IN-111, Y-90, CR-51)
        • 4.2.1.2     PET, BASED ON ISOTOPES
          • 4.2.1.2.1     FLUORODEOXYGLUCOSE (18F-FDG)
            • 4.2.1.2.1.1     SUPPLY CHAIN ANALYSIS OF FLUORINE-18 (F-18)
          • 4.2.1.2.2     GALLIUM (GA-68)
            • 4.2.1.2.2.1     SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (GA-68)
            • 4.2.1.2.2.2     CHARACTERISTICS OF CURRENT GE-68/GA-68 GENERATORS
          • 4.2.1.2.3     RUBIDIUM (RB-82)
            • 4.2.1.2.3.1     PRODUCTION ANALYSIS OF STRONTIUM (SR-82)/ RUBIDIUM (RB-82)
          • 4.2.1.2.4     OTHERS (C-11, N-13, O-15, CU-64)
      • 4.2.2     NUCLEAR MEDICINE FOR DIAGNOSIS, BASED ON APPLICATION
        • 4.2.2.1     SPECT ISOTOPES BASED ON APPLICATION
          • 4.2.2.1.1     CARDIOLOGY
          • 4.2.2.1.2     PULMONARY
          • 4.2.2.1.3     ONCOLOGY
          • 4.2.2.1.4     NEPHROLOGY
          • 4.2.2.1.5     NEUROLOGY
          • 4.2.2.1.6     INFLAMMATION
          • 4.2.2.1.7     THYROID GLANDS
          • 4.2.2.1.8     LYMPHOLOGY
          • 4.2.2.1.9     OTHERS
        • 4.2.2.2     PET ISOTOPES, BASED ON APPLICATION
          • 4.2.2.2.1     ONCOLOGY
          • 4.2.2.2.2     NEUROLOGY
          • 4.2.2.2.3     CARDIOLOGY
          • 4.2.2.2.4     INFLAMMATION
          • 4.2.2.2.5     OTHERS
    • 4.3     THERAPEUTICS
      • 4.3.1     BETA RADIATION THERAPY
        • 4.3.1.1     YTTRIUM (Y-90)
        • 4.3.1.2     IODINE (I-131)
        • 4.3.1.3     LUTETIUM (LU-177)
          • 4.3.1.3.1     DEMAND AND PRODUCTION ANALYSIS OF LUTETIUM-177 (LU-177)
        • 4.3.1.4     SAMARIUM (SM-153)
        • 4.3.1.5     RHENIUM (RE-186)
        • 4.3.1.6     STRONTIUM (SR-89)
        • 4.3.1.7     ERBIUM (ER-169)
        • 4.3.1.8     OTHERS
      • 4.3.2     ALPHA RADIATION THERAPY
        • 4.3.2.1     RADIUM (RA-223)
          • 4.3.2.1.1     ANALYSIS OF RADIUM-223 (RA-223)
        • 4.3.2.2     EMERGING ALPHA RADIATION ISOTOPES (AC-225 AND OTHERS)
          • 4.3.2.2.1     PRODUCTION ANALYSIS OF ACTINIUM-225 (AC-225) AND BISMUTH-213 (BI-213)
          • 4.3.2.2.2     ASTATINE (AT-211)
          • 4.3.2.2.3     LEAD (PB-212)/BISMUTH (BI-212)
          • 4.3.2.2.4     RADIUM (RA-224)
          • 4.3.2.2.5     THORIUM(TH-227)
          • 4.3.2.2.6     OTHERS
      • 4.3.3     BRACHYTHERAPY, BASED ON ISOTOPES
        • 4.3.3.1     IODINE (I-125)
        • 4.3.3.2     CESIUM (CS-131)
        • 4.3.3.3     IRIDIUM (IR-192)
        • 4.3.3.4     PALLADIUM (PD-103)
        • 4.3.3.5     OTHERS
      • 4.3.4     NUCLEAR MEDICINE THERAPEUTICS, BASED ON APPLICATION
        • 4.3.4.1     PROSTATE CANCER
        • 4.3.4.2     THYROID CANCER
        • 4.3.4.3     LIVER CANCER
        • 4.3.4.4     GEP-NET THERAPEUTICS
        • 4.3.4.5     METASTATIC BONE CANCER THERAPEUTICS
        • 4.3.4.6     BREAST CANCER THERAPEUTICS
        • 4.3.4.7     OTHER APPLICATIONS
  • 5     NUCLEAR MEDICINE GLOBAL MARKET, BASED ON END-USERS
    • 5.1     INTRODUCTION
    • 5.2     HOSPITALS
    • 5.3     AMBULATORY CENTERS
    • 5.4     DIAGNOSTIC CENTERS
    • 5.5     OTHER END-USERS
  • 6     NUCLEAR MEDICINE GLOBAL MARKET BASED ON REGION
    • 6.1     INTRODUCTION
    • 6.2     NORTH AMERICA
      • 6.2.1     U.S.
      • 6.2.2     REST OF N.A.
    • 6.3     EUROPE
      • 6.3.1     GERMANY
      • 6.3.2     FRANCE
      • 6.3.3     ITALY
      • 6.3.4     REST OF E.U.
    • 6.4     APAC
      • 6.4.1     JAPAN
      • 6.4.2     CHINA
      • 6.4.3     SOUTH KOREA
      • 6.4.4     REST OF APAC
    • 6.5     REST OF THE WORLD
      • 6.5.1     LATIN AMERICA & CARIBBEAN
      • 6.5.2     MIDDLE EAST
      • 6.5.3     AFRICA
        • 6.5.3.1     SOUTH AFRICA
  • 7     COMPETITIVE LANDSCAPE
    • 7.1     INTRODUCTION
    • 7.2     APPROVALS
    • 7.3     AGREEMENT/COLLABORATION
    • 7.4     ACQUISITION
    • 7.5     PRODUCT LAUNCH
    • 7.6     OTHERS
  • 8     MAJOR PLAYER PROFILES
    • 8.1     BAYER GROUP
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     BRACCO S.P.A
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     CARDINAL HEALTH INC.
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.)
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     CURIUM PHARMA
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     PRODUCT PORTFOLIO
      • 8.5.4     KEY DEVELOPMENTS
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     FUJIFILM HOLDINGS CORPORATION
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     PRODUCT PORTFOLIO
      • 8.6.4     KEY DEVELOPMENTS
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     GE HEALTHCARE
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     JUBILANT PHARMOVA
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     LANTHEUS MEDICAL IMAGING INC.
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.1     NOVARTIS INTERNATIONAL AG
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS
    • 8.11     SUMITOMO CHEMICALS
      • 8.11.1     OVERVIEW
      • 8.11.2     FINANCIALS
      • 8.11.3     PRODUCT PORTFOLIO
      • 8.11.4     KEY DEVELOPMENTS
      • 8.11.5     BUSINESS STRATEGY
      • 8.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 2     REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES
      • TABLE 3     NUCLEAR MEDICINE CLINICAL TRIALS
      • TABLE 4     TECHNETIUM (TC-99M) CURRENT IRRADIATORS
      • TABLE 5     TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
      • TABLE 6     TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
      • TABLE 7     TECHNETIUM (TC-99M) CURRENT PROCESSORS
      • TABLE 8     POTENTIAL PROCESSORS ENTERING THE GLOBAL SUPPLY CHAIN
      • TABLE 9     FDA APPROVED RADIOPHARMACEUTICALS
      • TABLE 10     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
      • TABLE 11     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2020-2030) ($MN)
      • TABLE 12     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 13     NUCLEAR MEDICINE SPECT AND PET OVERALL PROCEDURAL VOLUME (2021) (NOS.)
      • TABLE 14     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 15     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 16     TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 17     THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 18     GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 19     IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 20     XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 21     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 22     OTHER SPECT ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 23     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 24     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 25     FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 26     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 27     GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS
      • TABLE 28     RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 29     STRONTIUM (SR-82)/RUBIDIUM (RB-82) GENERATOR SUPPLIERS
      • TABLE 30     OTHER PET ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 31     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
      • TABLE 32     CARDIOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 33     PULMONARY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 34     ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 35     NEPHROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 36     NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 37     INFLAMMATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 38     THYROID GLANDS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 39     LYMPHOLOGY SPECT GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 40     OTHER SPECT APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 41     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 42     ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 43     NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 44     CARDIOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 45     INFLAMMATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 46     OTHER PET APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 47     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
      • TABLE 48     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 49     BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 50     BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 51     YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 52     IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 53     LUTETIUM (LU-177) SUPPLIERS AND PRODUCTION CAPACITY
      • TABLE 54     LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 55     LUTETIUM (LU-177) NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2021
      • TABLE 56     SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 57     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 58     STRONTIUM (SR-89) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 59     ERBIUM (ER-169) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 60     OTHER BETA RADIATION THERAPY ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 61     ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 62     ACTINIUM (AC-225) CURRENT AND FUTURE SUPPLIERS
      • TABLE 63     ASTATINE (AT-211) CURRENT SUPPLIERS
      • TABLE 64     BRACHYTHERAPY GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 65     BRACHYTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 66     IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 67     CESIUM (CS-131) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 68     IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 69     PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 70     OTHER BRACHYTHERAPY ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 71     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
      • TABLE 72     PROSTATE CANCER THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 73     THYROID CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 74     LIVER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 75     GEP-NET GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 76     METASTATIC BONE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 77     BREAST CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 78     OTHER THERAPEUTIC APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 79     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
      • TABLE 80     HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 81     AMBULATORY CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 82     DIAGNOSTIC CENTERS END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 83     OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 84     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • TABLE 85     NORTH AMERICA INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
      • TABLE 86     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
      • TABLE 87     NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
      • TABLE 88     NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 89     NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
      • TABLE 90     NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 91     NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 92     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
      • TABLE 93     NORTH AMERICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
      • TABLE 94     NORTH AMERICA NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
      • TABLE 95     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 96     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
      • TABLE 97     NORTH AMERICA NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
      • TABLE 98     EUROPE INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
      • TABLE 99     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
      • TABLE 100     EUROPE NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
      • TABLE 101     EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 102     EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 103     EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 104     EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 105     EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
      • TABLE 106     EUROPE NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 107     EUROPE BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
      • TABLE 108     EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 109     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
      • TABLE 110     EUROPE NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
      • TABLE 111     APAC INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
      • TABLE 112     APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
      • TABLE 113     APAC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
      • TABLE 114     APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
      • TABLE 115     APAC NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 116     APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 117     APAC NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 118     APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
      • TABLE 119     APAC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 120     APAC BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 121     APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
      • TABLE 122     APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
      • TABLE 123     APAC NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
      • TABLE 124     ROW INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
      • TABLE 125     ROW NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
      • TABLE 126     ROW NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
      • TABLE 127     ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 128     ROW NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 129     ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 130     ROW NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 131     ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
      • TABLE 132     ROW NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 133     ROW BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
      • TABLE 134     ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
      • TABLE 135     ROW NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
      • TABLE 136     ROW NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
      • TABLE 137     AFRICA NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($ K)
      • TABLE 138     SOUTH AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($ K)
      • TABLE 139     SOUTH AFRICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($ K)
      • TABLE 140     SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
      • TABLE 141     SOUTH AFRICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
      • TABLE 142     SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
      • TABLE 143     SOUTH AFRICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
      • TABLE 144     SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($ K)
      • TABLE 145     SOUTH AFRICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
      • TABLE 146     SOUTH AFRICA BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
      • TABLE 147     SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
      • TABLE 148     SOUTH AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($ K)
      • TABLE 149     APPROVALS (2019-2020)
      • TABLE 150     COLLABORATION (2020-2021)
      • TABLE 151     ACQUISITION (2020-2021)
      • TABLE 152     PRODUCT LAUNCH (2020-2021)
      • TABLE 153     OTHERS (2020-2021)
      • TABLE 154     BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
      • TABLE 155     BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
      • TABLE 156     BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
      • TABLE 157     CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2019-2021) ($MN)
      • TABLE 158     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2019 -2021) ($MN)
      • TABLE 159     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
      • TABLE 160     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019– 2021) (Q2) ($MN)
      • TABLE 161     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
      • TABLE 162     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2019 – 2021) (Q2) ($MN)
      • TABLE 163     GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2019–2021) (Q3) ($MN)
      • TABLE 164     GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
      • TABLE 165     GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2019 –2021) (Q2) ($MN)
      • TABLE 166     JUBILANT PHARMOVA: TOTAL REVENUE AND R&D EXPENSES (2019–2021) (Q2) ($MN)
      • TABLE 167     JUBILANT PHARMOVA: TOTAL REVENUE, BY SEGMENTS (2019–2021) (Q2) ($MN)
      • TABLE 168     JUBILANT PHARMOVA: PHARMACEUTICAL TOTAL REVENUE, BY SEGMENTS (2019–2021) (Q2) ($MN)
      • TABLE 169     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
      • TABLE 170     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2019-2021) (Q3) ($MN)
      • TABLE 171     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3)
      • TABLE 172     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
      • TABLE 173     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
      • TABLE 174     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
      • TABLE 175     SUMITOMO CHEMICALS: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
      • TABLE 176     SUMITOMO CHEMICALS: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
      • TABLE 177     SUMITOMO CHEMICALS: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE, BASED ON REGION, (2020-2030) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NUCLEAR MEDICINE GLOBAL MARKET
      • FIGURE 3     NUCLEAR MEDICINE GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     DIAGNOSTICS NUCLEAR GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 8     THERAPEUTIC NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 9     MARKET DYNAMICS
      • FIGURE 10     TECHNETIUM-99M: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     NUCLEAR MEDICINE MARKET: PORTER’S ANALYSIS
      • FIGURE 12     NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2021 (%)
      • FIGURE 13     SPECT ISOTOPES: MAJOR PLAYER MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 14     PET ISOTOPES: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 15     NUCLEAR MEDICINE THERAPEUTICS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 16     TC -99M: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 17     F-18: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 18     GA-68: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 19     SR-82 IRRADIATORS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 20     SR-82 SEPARATION: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 21     SR-82/RB-82 GENERATORS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
      • FIGURE 22     SPECT SCANNERS GLOBAL AND REGIONAL INSTALLED BASE (2021)
      • FIGURE 23     PET SCANNERS GLOBAL AND REGIONAL INSTALLED BASE (2021)
      • FIGURE 24     CYCLOTRONS GLOBAL AND REGIONAL INSTALLED BASE (2021)
      • FIGURE 25     NUCLEAR MEDICINE GLOBAL MARKET SHARE, BASED ON MODALITY, (2021 V/S 2030) (%)
      • FIGURE 26     NUCLEAR MEDICINE ISOTOPES, BASED ON MODALITY
      • FIGURE 27     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET SHARE, BASED ON PRODUCTS, (2021 V/S 2030) (%)
      • FIGURE 28     SPECT GLOBAL PROCEDURAL VOLUME BASED ON REGION AND COUNTRY (2021) (NOS.)
      • FIGURE 29     PET GLOBAL PROCEDURAL VOLUME BASED ON REGION AND COUNTRY (2021)(NOS.)
      • FIGURE 30     NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
      • FIGURE 31     THALLIUM (TL-201) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 32     GALLIUM (GA-67) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 33     IODINE (I-123) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 34     IODINE (I-123) SUPPLY CHAIN
      • FIGURE 35     XENON (XE-133) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 36     RHENIUM (RE-186) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 37     NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 38     FLUORINE-18 (F-18) SUPPLY CHAIN
      • FIGURE 39     SUPPLY CHAIN OF GE-68/GA-68 GENERATOR
      • FIGURE 40     NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021) (%)
      • FIGURE 41     NUCLEAR MEDICINE SPECT ISOTOPES, BASED ON APPLICATION
      • FIGURE 42     CARDIOLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 43     NEPHROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 44     NEUROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 45     INFLAMMATION GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 46     NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 47     NUCLEAR MEDICINE PET ISOTOPES, BASED ON APPLICATION
      • FIGURE 48     CARDIOLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 49     INFLAMMATION GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 50     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
      • FIGURE 51     BETA RADIATION THERAPY GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 52     IODINE(I-131) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 53     LU-177 BASED THERAPY (LUTATHERA), GLOBAL MARKET PENETRATION, (2021) (%)
      • FIGURE 54     LU-177 BASED THERAPY (LUTATHERA), NORTH AMERICA MARKET PENETRATION, (2021) (%)
      • FIGURE 55     LU-177 BASED THERAPY (LUTATHERA), EUROPE MARKET PENETRATION, (2021)(%)
      • FIGURE 56     LU-177 BASED THERAPY (LUTATHERA), ASIA-PACIFIC MARKET PENETRATION, (2021) (%)
      • FIGURE 57     LU-177 BASED THERAPY (LUTATHERA), ROW MARKET PENETRATION, (2021) (%)
      • FIGURE 58     SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 59     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 60     ERBIUM (ER-169) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 61     NUCLEAR MEDICINE BRACHYTHERAPY GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 62     BRACHYTHERAPY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 63     IODINE (I-125) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 64     CESIUM (CS-131) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 65     IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 66     PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 67     OTHER BRACHYTHERAPY ISOTOPES GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 68     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 69     NUCLEAR MEDICINE THERAPEUTIC ISOTOPES, BASED ON APPLICATION
      • FIGURE 70     PROSTATE CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 71     THYROID CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 72     BREAST CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
      • FIGURE 73     NUCLEAR MEDICINE GLOBAL MARKET SHARE, BASED ON END-USERS, (2021 V/S 2030) (%)
      • FIGURE 74     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION (2020-2030) ($MN), CAGR (%)
      • FIGURE 75     NUCLEAR MEDICINE GLOBAL MARKET SHARE BASED ON REGION AND MARKET REVENUE BASED ON COUNTRY, (2021) (%) ($MN)
      • FIGURE 76     NORTH AMERICA NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
      • FIGURE 77     NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BASED ON PRODUCT, (2021 V/S 2030) (%)
      • FIGURE 78     NORTH AMERICA SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 79     NORTH AMERICA PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
      • FIGURE 80     NORTH AMERICA SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
      • FIGURE 81     NORTH AMERICA PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 82     NORTH AMERICA THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
      • FIGURE 83     NORTH AMERICA BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 84     NORTH AMERICA BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
      • FIGURE 85     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 86     NORTH AMERICA NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
      • FIGURE 87     NORTH AMERICA NUCLEAR MEDICINE SHARE, BASED ON COUNTRY, (2021 V/S 2030) (%)
      • FIGURE 88     U.S. NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 89     U.S. NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 90     U.S. NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND U.S. NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 91     REST OF NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 92     REST OF NORTH AMERICA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 93     REST OF NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND THE REST OF NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 94      EUROPE NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
      • FIGURE 95     EUROPE NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
      • FIGURE 96     EUROPE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 97     EUROPE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
      • FIGURE 98     EUROPE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
      • FIGURE 99     EUROPE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 100     EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
      • FIGURE 101     EUROPE BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 102     EUROPE BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 103     EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 104     EUROPE NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
      • FIGURE 105     EUROPE NUCLEAR MEDICINE SHARE, BY COUNTRY, (2021 V/S 2030) (%)
      • FIGURE 106     GERMANY NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND GERMANY DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 107     GERMANY NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 108     GERMANY NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 109     FRANCE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND FRANCE DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 110     FRANCE NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 111     FRANCE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND FRANCE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 112     ITALY NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND ITALY DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 113     ITALY NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 114     ITALY NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND ITALY NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 115     REST OF EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND REST OF EUROPE DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 116     REST OF EUROPE NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 117     REST OF EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND REST OF EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 118     APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
      • FIGURE 119     APAC NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
      • FIGURE 120     APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 121     APAC NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
      • FIGURE 122     APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
      • FIGURE 123     APAC NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 124     APAC NUCLEAR MEDICINE THERAPEUTICS MARKET SHARE, BY RADIATION TYPE, (2021 V/S 2030) (%)
      • FIGURE 125     APAC BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 126     APAC BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 127     APAC NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 128     APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
      • FIGURE 129     APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 V/S 2030) (%)
      • FIGURE 130     JAPAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND JAPAN DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 131     JAPAN NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 132     JAPAN NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BASED ON APPLICATION AND JAPAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 133     CHINA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND CHINA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 134     CHINA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 135     CHINA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND CHINA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 136     SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND SOUTH KOREA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 137     SOUTH KOREA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 138     SOUTH KOREA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BASED ON APPLICATION AND SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 139     REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, AND THE REST OF APAC DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 140     REST OF APAC NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 141     REST OF APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND THE REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 142     ROW NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
      • FIGURE 143     ROW NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
      • FIGURE 144     ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 145     ROW NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
      • FIGURE 146     ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
      • FIGURE 147     ROW NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 148     ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
      • FIGURE 149     ROW BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 150     ROW BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 151     ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 152     ROW NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 VS 2030) (%)
      • FIGURE 153     ROW NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 VS 2030) (%)
      • FIGURE 154     LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND LATIN AMERICA & CARIBBEAN DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030)($MN)
      • FIGURE 155     LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 156     LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 157     MIDDLE EAST NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND MIDDLE EAST DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 158     MIDDLE EAST NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 159     MIDDLE EAST NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND MIDDLE EAST NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 160     AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND AFRICA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
      • FIGURE 161     AFRICA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
      • FIGURE 162     AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
      • FIGURE 163     AFRICA NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 VS 2030) (%)
      • FIGURE 164     SOUTH AFRICA NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
      • FIGURE 165     SOUTH AFRICA NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
      • FIGURE 166     SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 167     SOUTH AFRICA NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
      • FIGURE 168     SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
      • FIGURE 169     SOUTH AFRICA NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 170     SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
      • FIGURE 171     SOUTH AFRICA BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 172     SOUTH AFRICA BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
      • FIGURE 173     SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
      • FIGURE 174     SOUTH AFRICA NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 VS 2030) (%)
      • FIGURE 175     KEY GROWTH STRATEGIES (2020-2021)
      • FIGURE 176     SWOT: BAYER GROUP
      • FIGURE 177     SWOT: BRACCO S.P.A
      • FIGURE 178     SWOT: CARDINAL HEALTH, INC.
      • FIGURE 179     SWOT: CDH INVESTMENTS SOURCE: ANNUAL/FINANCIAL REPORTS, SEC FILINGS, INVESTOR PRESENTATIONS, PRESS RELEASES AND IQ4I ANALYSIS
      • FIGURE 180     SWOT: CURIUM PHARMA
      • FIGURE 181     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 182     SWOT: GE HEALTHCARE
      • FIGURE 183     SWOT: JUBILANT LIFESCIENCES
      • FIGURE 184     SWOT: LANTHEUS MEDICAL IMAGING INC.
      • FIGURE 185     SWOT: NOVARTIS INTERNATIONAL AG
      • FIGURE 186     SWOT: SUMITOMO CHEMICALS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ALLIANCE MEDICAL (LIFE MOLECULAR IMAGING)
      • 2     ARRONAX CYCLOTRON
      • 3     ARTMS, INC. (ALTERNATIVE RADIOISOTOPE TECHNOLOGIES FOR MEDICAL SCIENCE)
      • 4     AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION (ANSTO)
      • 5     BAYER GROUP
      • 6     BEST MEDICAL INTERNATIONAL, INC.,
      • 7     BOARD OF RADIATION & ISOTOPE TECHNOLOGY (BRIT)
      • 8     BOSTON SCIENTIFIC CORPORATION (BTG INTERNATIONAL LTD)
      • 9     BRACCO IMAGING S.P.A ( BLUE EARTH DIAGNOSIS)
      • 10     BV CYCLOTRON VU
      • 11     BWX TECHNOLOGIES (SOTERA HEALTH LLC (NORDION INC))
      • 12     CARDINAL HEALTH
      • 13     CARECAMP, INC
      • 14     CDH INVESTMENTS (SIRTEX MEDICAL LTD.)
      • 15     CENTER OF MOLECULAR RESEARCH (CMR)
      • 16     CURIUM PHARMA
      • 17     CYCLOPHARM LIMITED
      • 18     CYCLOTEK
      • 19     DIAMED
      • 20     DUCHEMBIO, INC
      • 21     ECKERT & ZIEGLER STRAHLEN
      • 22     ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
      • 23     ELI LILLY & CO (AVID RADIOPHARMACEUTICALS)
      • 24     FUJIFILM HOLDINGS CORPORATION/PEPTIDREAM
      • 25     FUTURECHEM CO., LTD
      • 26     GE COMPANY
      • 27     GT MEDICAL TECHNOLOGIES INC
      • 28     HILA PHARMA LTD
      • 29     HUAYI TECHNOLOGY CO., LTD (HUAYI ISOTOPES CO)
      • 30     INSTITUT RADIOFARMACIA APLICADA DE BARCELONA (IARB)
      • 31     INSTITUTE OF ISOTOPES
      • 32     INTERNATIONAL ISOTOPES INC.
      • 33     IRE ELIT
      • 34     ISOAID LLC
      • 35     ISO-ANALYTICAL LTD.
      • 36     ISOFLEX ISOTOPES
      • 37     ISOLOGIC
      • 38     ISORAD LTD
      • 39     ISORAY INC.,
      • 40     ISO-TEX DIAGNOSTICS, INC.
      • 41     ISOTOPIA MOLECULAR IMAGING LTD.
      • 42     ITHEMBA LABS
      • 43     ITM ISOTOPEN TECHNOLOGIEN MÜNCHEN AG
      • 44     JSC ISOTOPE
      • 45     JUBILANT PHARMOVA (INDIA)
      • 46     KOREA ATOMIC ENERGY RESEARCH INSTITUTE
      • 47     LANTHEUS MEDICAL IMAGING
      • 48     LOS ALAMOS NATIONAL LABORATORY (LANL)
      • 49     MITSUBISHI CHEMICAL HOLDINGS (TAIYO NIPPON SANSO CORPORATION)
      • 50     MOLTEK
      • 51     NAVIDEA BIOPHARMACEUTICAL INC.
      • 52     NIOWAVE INC.
      • 53     NORTHSTAR MEDICAL RADIOISOTOPES, LLC
      • 54     NOVARTIS INTERNATIONAL AG (AAA) (SWITZERLAND)
      • 55     NUCLEAR RESEARCH AND CONSULTANCY GROUP (NRG)
      • 56     NUKEM ISOTOPES, GMBH
      • 57     OTSUKA PHARMACEUTICAL (CAMBRIDGE ISOTOPE LABORATORIES, INC.)
      • 58     PARS ISOTOPE
      • 59     PERKINELMER INC.
      • 60     PERMA-FIX ENVIRONMENTAL SERVICES, INC. (PERMA FIX MEDICAL SA)
      • 61     PET PHARM BIOTECH CO., LTD
      • 62     PLUS THERAPEUTICS
      • 63     POLATOM
      • 64     POSITRON PHARMA S.A.
      • 65     QMX LABORATORIES
      • 66     RADIOMEDIX, INC.
      • 67     RADIOPREPARAT
      • 68     ROSATOM
      • 69     ROTOP PHARMAKA GMBH
      • 70     SAMYOUNG UNITECH CO., LTD
      • 71     SHANGHAI GMS PHARMA
      • 72     SHANGHAI RESEARCH INSTITUTE OF CHEMICAL INDUSTRY
      • 73     SHINE TECHNOLOGIES, LLC
      • 74     SIEMENS HEALTHINEERS
      • 75     SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NTP)
      • 76     SUMITOMO CHEMICAL CO., LTD (NIHON-MEDI PHYSICS CO., LTD.)
      • 77     SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 78     SWAN ISOTOPEN AG
      • 79     TELIX PHARMACEUTICALS LIMITED
      • 80     TERUMO CORPORATION
      • 81     TEVA PHARMACEUTICAL INDUSTRIES LTD (AUSPEX PHARMACEUTICALS)
      • 82     THERAGENICS CORPORATION
      • 83     THERAGNOSTICS LTD